# Bioequivalence Study for Gemigliptin/Metformin 50/1000 mg and Coadministration of Gemigliptin 50 mg and Metformin 1000 mg.

> **NCT04050098** · PHASE1 · UNKNOWN · sponsor: **LG Chem** · enrollment: 24 (estimated)

## Conditions studied

- Type2 Diabetes

## Interventions

- **DRUG:** gemigliptin 50 mg and metformin hydrochloride 1000 mg prolonged release
- **DRUG:** Gemigliptin tartrate sesquihydrate and metformin

## Key facts

- **NCT ID:** NCT04050098
- **Lead sponsor:** LG Chem
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11-01
- **Primary completion:** 2019-11-30
- **Final completion:** 2019-11-30
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2019-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04050098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04050098, "Bioequivalence Study for Gemigliptin/Metformin 50/1000 mg and Coadministration of Gemigliptin 50 mg and Metformin 1000 mg.". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04050098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*